Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05580614 · ClinicalTrials.gov registry record · NA
Paired tVNS With ERP in OCD
A NA study of OCD, sponsored by University of Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05580614: Recruiting NA study of OCD, sponsored by University of Florida.
NCT05580614 is a NA study of OCD that is actively recruiting participants, run by University of Florida. The registered enrollment target is 56 participants, below the 815-participant average among 18 other OCD trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05580614, a NA study of OCD, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability information from therapists and patients with OCD, effect sizes on real world clinical outcomes for the combinatory treatment, and mechanistic data on brain changes associated with treatment.
Primary Outcome
A test to rate the severity of obsessive-compulsive disorder (OCD) symptoms. The 10 Y-BOCS items are each scored on a four-point scale from 0 = "no symptoms" to 4 = "extreme symptoms." The sum of the first five items is a severity index for obsessions, and the sum of the last five an index for compulsions. Total scores on the measure range from 0 to 40, with a score of 0-7 indicating subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme sympto
Conditions Studied
Interventions
- DEVICE Sham
- DEVICE tVNS
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT05580614 shows while recruiting
NCT05580614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 815-participant average among 18 other OCD trials with a reported enrollment target (93% lower).
The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT05580614 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05580614 about?
NCT05580614 is a clinical study titled "Paired tVNS With ERP in OCD". In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability informatio...
What is the current status of trial NCT05580614?
This trial is currently recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2022-06-27. Estimated completion is 2026-08-31.
What conditions does trial NCT05580614 study?
This clinical trial studies the following conditions: OCD.
What interventions are being tested in trial NCT05580614?
The interventions under investigation include: Sham (DEVICE), tVNS (DEVICE).
Who is sponsoring clinical trial NCT05580614?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05580614 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OCD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05580614's enrollment target sits among peer trials
56 11th of 18 higher than 8 of 18 other OCD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OCD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation for a Novel OCD Biomarker and Treatment
RECRUITING · NA
-
Personalized DBS for OCD Guided by Stereoencephalography Mapping
RECRUITING · NA
-
Neurostimulation Versus Therapy for Problems With Emotions
RECRUITING · NA
-
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI